Advaccine Biopharmaceuticals Suzhou Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Advaccine Biopharmaceuticals Suzhou Co., Ltd.
Inovio looks to countries outside the US to continue late-stage development of its vaccine, while a South Korean firm strikes a supply deal with Indonesia and Japan approves a new drug for COVID-19.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.